At the 2025 World Conference on Genitourinary Cancers (World GU), Oncology Decoded hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, spoke w...

Oncology Decoded hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, traveled to the 2025 World Conference on Genitourinary Cancers (World GU)...

During the Society of Hematological Oncology (SOHO) 2025 Annual Meeting, Lorenzo Falchi, MD, an oncologist and hematologist specializing in lymphoma a...

The addition of surufatinib (Sulanda) to durvalumab (Imfinzi), etoposide, and platinum-based chemotherapy displayed promising efficacy and a manageabl...

As part of the IASLC 2025 World Conference on Lung Cancer (WCLC), experts from around the world convened in Barcelona, Spain, to exhibit updated findi...

At the Society of Hematological Oncology 2025 Annual Meeting, Prithviraj Bose, MD, delivered a presentation titled “Individualizing Treatment Selectio...

First-line durvalumab (Imfinzi) plus etoposide and either carboplatin or cisplatin (EP) produced a significant improvement in overall survival (OS) co...

The FDA has approved selumetinib (Koselugo) granules and capsules for the treatment of pediatric patients who are 1 or older with neurofibromatosis ty...

Interim results from the phase 2 pivotal portion of the phase 1/2 PYNNACLE trial (NCT04585750) demonstrated that rezatapopt (PC14586) was efficacious...

The FDA has accepted a new drug application (NDA) for relacorilant (CORT125134) as a treatment for patients with platinum-resistant ovarian cancer, ac...